Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693013 | 0.83 | HTR1A (0.51) | CYP2D6SIGMAR1DRD2CHRM3CHRM2 | |
| SCHEMBL13120462 | 0.83 | HTR1A (0.51) | CYP2D6SIGMAR1DRD2CHRM3CHRM2 | |
| SCHEMBL2017755 | 0.81 | SIGMAR1 (0.46) | CYP2D6SIGMAR1DRD2CHRM3CHRM2 | |
| SCHEMBL2014035 | 0.81 | DRD2 (0.47) | CYP2D6SIGMAR1DRD2CHRM3CHRM2 | |
| SCHEMBL692590 | 0.78 | CYP2D6 (0.44) | CYP2D6SIGMAR1DRD2CHRM3CHRM2 | |
| SCHEMBL2014482 | 0.78 | CYP2D6 (0.44) | CYP2D6SIGMAR1DRD2CHRM3CHRM2 | |
| SCHEMBL2012961 | 0.78 | CYP2D6 (0.47) | CYP2D6SIGMAR1DRD2DRD4DRD3 | |
| SCHEMBL3629649 | 0.75 | MAPT (0.47) | CYP2D6DRD2HTR1AADRA1DADRA1A | |
| SCHEMBL12572987 | 0.75 | CYP2D6 (0.43) | CYP2D6DRD2CHRM3CHRM2DRD4 | |
| SCHEMBL2017764 | 0.75 | LMNA (0.44) | CYP2D6DRD2CHRM3CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9701679-B2 | Modulators of 5-HT receptors and methods of use thereof | Abb Vie Deutschland GmbH & Co. KG (DE) | 2017-07-11 | — | — | US | disclosed |
| EP-2421870-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2522671-B1 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-8846663-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2013-11-21 | — | — | US | disclosed |
| US-8518933-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2522671-A2 | Modulators of 5-HT receptors and methods of use thereof | Abbott Laboratories (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CYP2D6 358/4885SIGMAR1 77/4885DRD2 73/4885 |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CYP2D6 358/4885SIGMAR1 77/4885DRD2 73/4885 |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CYP2D6 358/4885SIGMAR1 77/4885DRD2 73/4885 |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CYP2D6 358/4885SIGMAR1 77/4885DRD2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.